Novartis muscle wasting drug gets `breakthrough` status
Zurich: Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM).
The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
sIBM is a rare yet potentially life-threatening muscle-wasting condition. Patients suffering from the disease can gradually lose the ability to walk. There are currently no approved treatments, according to Novartis.
Bimagrumab was developed by Novartis in collaboration with Morphosys. The drug works by stimulating muscle growth by blocking from inhibitory molecules.
More from India
More from World
More from Sports
More from Entertaiment
- Sonakshi Sinha silences Twitter troll for calling her ugly and it's epic!
- Furkan, not Tiger Memon, arrested in Pakistan
- Sheena Bora murder case: Peter Mukerjea's statement recorded, police search his Worli residence
- Modi effect! Pakistan-occupied Kashmir wants to be part of India
- Rafiabad encounter ends with one terrorist dead; an Army jawan also martyred